Uveitis Treatment Trials—A Cross-study Perspective

REFERENCES

• Martel JN, Esterberg E, Nagpal A, Acharya NR. Infliximab and adalimumab for uveitis. Ocul Immunol Inflamm. 2012;18–26.
   PubMedGoogle Scholar
• Jabs DA, Nussenblatt RB, Rosenbaum JT. Standardization of Uveitis Nomenclature (SUN) Working Group. Standardization of uveitis nomenclature for reporting clinical data. Results of the First International Workshop. Am J Ophthalmol. 2005;140:509–516.
   PubMed Web of Science ®Google Scholar
• Jabs DA. Improving the reporting of clinical case series. Am J Ophthalmol. 2005;139:900–905.
   PubMed Web of Science ®Google Scholar
• Cunningham ET, Zierhut M. TNF inhibitors for uveitis: balancing efficacy and safety. Ocul Immunol Inflamm. 2010;18:421–423.
   PubMed Web of Science ®Google Scholar
• Larson T, Nussenblatt RB, Sen HN. Emerging drugs for uveitis. Expert Opin Emerg Drugs. 2011;16:309–322.
   PubMed Web of Science ®Google Scholar
• Benitah NR, Sobrin L, Papaliodis GN. The use of biologic agents in the treatment of ocular manifestations of Behcet’s disease. Semin Ophthalmol. 2011;26:295–303.
   PubMed Web of Science ®Google Scholar
• Heiligenhaus A, Thurau S, Hennig M, Grajewski RS, Wildner G. Anti-inflammatory treatment of uveitis with biologicals: new treatment options that reflect pathogenetic knowledge of the disease. Graefes Arch Clin Exp Ophthalmol. 2010;248:1531–1551.
   PubMed Web of Science ®Google Scholar
• Rosenbaum JT. Future for biological therapy for uveitis. Curr Opin Ophthalmol. 2010;21:473–477.
   PubMed Web of Science ®Google Scholar
• Hemmati HD, Dunn JP. Biologic therapy for uveitis. Expert Rev Ophthalmol. 2010;5:225–239.
   Google Scholar
• Sharma SM, Nestel AR, Lee RW, Dick AD. Clinical review: Anti-TNFalpha therapies in uveitis: perspective on 5 years of clinical experience. Ocul Immunol Inflamm. 2009;17:403–414.
   PubMed Web of Science ®Google Scholar
• Imrie FR, Dick AD. Biologics in the treatment of uveitis. Curr Opin Ophthalmol. 2007;18:481–486.
   PubMed Web of Science ®Google Scholar
• Lim L, Suhler EB, Smith JR. Biologic therapies for inflammatory eye disease. Clin Experiment Ophthalmol. 2006;34:365–374.
   PubMed Web of Science ®Google Scholar
• Markman M. Cross-trial comparisons in the oncology arena: when is this justified? Oncology. 2011;80:151–152. Epub 2011 Jun 14.
   PubMed Web of Science ®Google Scholar
• Hall D. Relative antiviral efficacy should not be inferred from cross-trial comparisons. HIV Med. 2007;8:570–571.
   PubMedGoogle Scholar
• Phillips A. Trial and error: cross-trial comparisons of antiretroviral regimens. AIDS. 2003;17:619–623.
   PubMedGoogle Scholar
• Kempen JH, Daniel E, Gangaputra S, et al. Methods for identifying long-term adverse effects of treatment in patients with eye diseases: the Systemic Immunosuppressive Therapy for Eye Diseases (SITE) Cohort Study. Ophthalmic Epidemiol. 2008;15:47–55.
   PubMed Web of Science ®Google Scholar
• Pasadhika S, Kempen JH, Newcomb CW, et al. Azathioprine for ocular inflammatory diseases. Am J Ophthalmol. 2009;148:500–509.e2.
   PubMed Web of Science ®Google Scholar
• Gangaputra S, Newcomb CW, Liesegang TL, et al. Systemic Immunosuppressive Therapy for Eye Diseases Cohort Study. Methotrexate for ocular inflammatory diseases. Ophthalmology. 2009;116:2188–98.e1.
   PubMed Web of Science ®Google Scholar
• Pujari SS, Kempen JH, Newcomb CW et al., Cyclophosphamide for ocular inflammatory diseases. Ophthalmology. 2010;117:356–365.
   PubMed Web of Science ®Google Scholar
• Kaçmaz RO, Kempen JH, Newcomb C, et al. Cyclosporine for ocular inflammatory diseases. Ophthalmology. 2010;117:576–584.
   PubMed Web of Science ®Google Scholar
• Daniel E, Thorne JE, Newcomb CW et al., Mycophenolate mofetil for ocular inflammation. Am J Ophthalmol. 2010;149:423–32.e1.
   PubMed Web of Science ®Google Scholar
• Kempen JH, Altaweel MM, Holbrook JT, Jabs DA, Sugar EA; Multicenter Uveitis Steroid Treatment Trial Research Group. The multicenter uveitis steroid treatment trial: rationale, design, and baseline characteristics. Am J Ophthalmol. 2010;149:550–561.e10.
   PubMed Web of Science ®Google Scholar
• Holbrook JT, Kempen JH, Prusakowski NA, Altaweel MM, Jabs DA; Multicenter Uveitis Steroid Treatment (MUST) Trial Research Group. Challenges in the design and implementation of the Multicenter Uveitis Steroid Treatment (MUST) Trial–lessons for comparative effectiveness trials. Clin Trials. 2011;8:736–743.
   PubMed Web of Science ®Google Scholar
• Kempen JH, Altaweel MM, Holbrook JT, et al. Multicenter Uveitis Steroid Treatment (MUST) Trial Research Group. Randomized comparison of systemic anti-inflammatory therapy versus fluocinolone acetonide implant for intermediate, posterior, and panuveitis: the multicenter uveitis steroid treatment trial. Ophthalmology.2011; 118:1916–1926. Epub 2011 Aug 15.
   PubMed Web of Science ®Google Scholar
• Nguyen QD, Hatef E, Kayen B, et al. A cross-sectional study of the current treatment patterns in noninfectious uveitis among specialists in the United States. Ophthalmology. 2011;118:184–190.
   PubMed Web of Science ®Google Scholar
• Cunningham ET Jr. Surveying uveitis specialists—a call for consensus. J Ophthalmic Inflamm Infect. 2012; DOI: 10.1007/s12348-012-0061-2.
   Google Scholar
• Callanan DG, Jaffe GJ, Martin DF, Pearson PA, Comstock TL. Treatment of posterior uveitis with a fluocinolone acetonide implant: three-year clinical trial results. Arch Ophthalmol. 2008;126:1191–1201.
   PubMed Web of Science ®Google Scholar
• Jaffe GJ, Martin D, Callanan D, Pearson PA, Levy B, Comstock T; Fluocinolone Acetonide Uveitis Study Group. Fluocinolone acetonide implant (Retisert) for noninfectious posterior uveitis: thirty-four-week results of a multicenter randomized clinical study. Ophthalmology. 2006;113:1020–1027.
   PubMed Web of Science ®Google Scholar
• Pavesio C, Zierhut M, Bairi K, Comstock TL, Usner DW; Fluocinolone Acetonide Study Group. Evaluation of an intravitreal fluocinolone acetonide implant versus standard systemic therapy in noninfectious posterior uveitis. Ophthalmology. 2010;117:567–75, 575.e1.
   PubMed Web of Science ®Google Scholar
• Goldstein DA, Godfrey DG, Hall A, et al. Intraocular pressure in patients with uveitis treated with fluocinolone acetonide implants. Arch Ophthalmol. 2007;125:1478–1485.
   PubMed Web of Science ®Google Scholar
• Bollinger K, Kim J, Lowder CY, Kaiser PK, Smith SD. Intraocular pressure outcome of patients with fluocinolone acetonide intravitreal implant for noninfectious uveitis. Ophthalmology. 2011;118:1927–1931.
   PubMed Web of Science ®Google Scholar
• Esterberg E, Acharya NR. Corticosteroid-sparing therapy: practice patterns among uveitis specialists. J Ophthalmic Inflamm Infect. 2011; Nov 6. [Epub ahead of print].
   PubMedGoogle Scholar
• Lee RW, Schewitz LP, Nicholson LB, Dayan CM, Dick AD. Steroid refractory CD4+ T cells in patients with sight-threatening uveitis. Invest Ophthalmol Vis Sci. 2009;50:4273–4278.
   PubMedGoogle Scholar
• Goldstein DA, Fontanilla FA, Kaul S, Sahin O, Tessler HH. Long-term follow-up of patients treated with short-term high-dose chlorambucil for sight-threatening ocular inflammation. Ophthalmology. 2002;109:370–377.
   PubMed Web of Science ®Google Scholar
• Birnbaum AD, Oh F, Sahin O, Little DM, Tessler HH, Goldstein DA. Chlorambucil and malignancy. Ophthalmology. 2010;117:1466–1466.e1.
   PubMed Web of Science ®Google Scholar
• Zaghetto JM, Yamamoto MM, Souza MB, Silva FT, Hirata CE, Olivalves E, Yamamoto JH. Chlorambucil and cyclosporine A in Brazilian patients with Behçet’s disease uveitis: a retrospective study. Arq Bras Oftalmol. 2010;73:40–46.
   PubMed Web of Science ®Google Scholar
• Stübiger N, Winterhalter S, Pleyer U, Doycheva D, Zierhut M, Deuter C. [Janus-faced?: Effects and side-effects of interferon therapy in ophthalmology]. Ophthalmologe. 2011;108:204–212.
   PubMedGoogle Scholar
• Deuter CM, Zierhut M, Möhle A, Vonthein R, Stöbiger N, Kötter I. Long-term remission after cessation of interferon-a treatment in patients with severe uveitis due to Behçet’s disease. Arthritis Rheum. 2010;62:2796–2805.
   PubMed Web of Science ®Google Scholar
• Butler NJ, Suhler EB, Rosenbaum JT. Interferon alpha 2b in the treatment of uveitic cystoid macular edema. Ocul Immunol Inflamm. 2012; 20:85–89.
   Google Scholar
• Deuter CM, Kötter I, Günaydin I, Stübiger N, Doycheva DG, Zierhut M. Efficacy and tolerability of interferon alpha treatment in patients with chronic cystoid macular oedema due to non-infectious uveitis. Br J Ophthalmol. 2009;93:906–913.
   PubMed Web of Science ®Google Scholar
• Deuter CM, Koetter I, Guenaydin I, Stuebiger N, Zierhut M. Interferon alfa-2a: a new treatment option for long lasting refractory cystoid macular edema in uveitis? A pilot study. Retina (Philadelphia, Pa). 2006;26:786–791.
   PubMed Web of Science ®Google Scholar
• Deuter CM, Gelisken F, Stübiger N, Zierhut M, Doycheva D. Successful treatment of chronic pseudophakic macular edema (Irvine-Gass syndrome) with interferon alpha: a report of three cases. Ocul Immunol Inflamm. 2011;19:216–218.
   PubMed Web of Science ®Google Scholar